France Biotech

France Biotech est un moteur de changement qui agit auprès des pouvoirs publics, des organisations économiques, de la recherche académique, des media et de la communauté des investisseurs notamment, pour favoriser l’émergence de la biotechnologie comme industrie de pointe prioritaire, et améliorer l’environnement économique, juridique, réglementaire et managérial de ces entreprises.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

news image

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

news image

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More
news image

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More
news image

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More
news image

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More
news image

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us